Chrysin / CYP2C9 Cancer Research Results

CHr, Chrysin: Click to Expand ⟱

Features:

Chrysin is found in passion flower and honey. It is a flavonoid.
-To reach plasma levels that might more closely match the concentrations used in in vitro studies (typically micromolar), considerably high doses or advanced delivery mechanisms would be necessary.
Chrysin is widely summarized as modulating PI3K/Akt and MAPK pathways in cancer.

Chrysin — Chrysin is a naturally occurring flavone-class flavonoid found in honey, propolis, passionflower, and several plants. Its oncology relevance is mainly preclinical: it shows multi-pathway anticancer activity in cell and animal models, but native oral chrysin has very poor systemic bioavailability and no established approved oncology use.

Primary mechanisms (ranked):

Suppression of PI3K/AKT survival signaling with downstream reduction in proliferation and survival programs.
Induction of mitochondrial apoptosis through Bax/Bcl-2 shift, mitochondrial membrane potential loss, cytochrome c release, and caspase activation.
Context-dependent ROS stress amplification in cancer cells, often linked to mitochondrial injury, ER stress, and apoptosis.
ER stress / unfolded-protein-response activation leading to autophagy or stress-to-death coupling.
Suppression of inflammatory, invasive, angiogenic, and metastatic signaling including NF-κB, MMPs, EMT, VEGF, and HIF-1α axes.
Secondary antioxidant / NRF2-linked cytoprotection in some normal-cell or injury models, which is context-dependent and not necessarily anticancer-selective.

Bioavailability / PK relevance: Native oral chrysin has very poor systemic exposure because of low aqueous solubility, extensive intestinal/hepatic glucuronidation and sulfation, and efflux; human oral bioavailability has been reported as extremely low, often summarized as below 1%. Formulation strategies such as nanoparticles, lipid systems, micelles, cyclodextrins, or structural analogues are commonly proposed for systemic translation.

In-vitro vs systemic exposure relevance: Most anticancer studies use micromolar in-vitro concentrations that are unlikely to be reached in plasma after ordinary oral chrysin. Local intestinal exposure may be more plausible than systemic tumor exposure, but systemic anticancer claims should be treated as formulation-dependent.
LipoMicel may increase bioavailability

Clinical evidence status: Preclinical. Evidence is strong enough for mechanistic oncology interest in cell and animal models, including combination/sensitization studies, but there is no mature clinical oncology evidence establishing therapeutic benefit.

-Note half-life 2 hrs, BioAv very poor often <1%
Pathways:
Graphical Pathways

- may induce ROS production
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓
- May Lower AntiOxidant defense in Cancer Cells: NRF2↓, GSH↓ HO1↓
- May Raise AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, Pro-Inflammatory Cytokines : IL-1β↓, TNF-α↓, IL-6↓,
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMP2↓, MMP9↓, TIMP2, uPA↓, VEGF↓, ROCK1↓, FAK↓, RhoA↓, NF-κB↓, ERK↓
- reactivate genes thereby inhibiting cancer cell growth : HDAC↓, P53↑, HSP↓,
- cause Cell cycle arrest : TumCCA↑, cyclin D1↓, CDK2↓, CDK4↓,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, FAK↓, ERK↓, EMT↓, TOP1↓, TET1↓,
- inhibits glycolysis and ATP depletion : HIF-1α↓, cMyc↓, GLUT1↓, LDH↓, HK2↓, PDKs↓, HK2↓, GRP78↑, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, PDGF↓, EGFR↓,
- Others: PI3K↓, AKT↓, STAT↓, Wnt↓, AMPK↓, ERK↓, JNK, TrxR,
- Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, Others(review target notes), Neuroprotective, Cognitive, Renoprotection, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells

Chrysin Mechanistic Profile

Rank	Pathway / Axis	Cancer Cells	Normal Cells	TSF	Primary Effect	Notes / Interpretation
1	PI3K AKT survival signaling	PI3K↓; AKT phosphorylation↓; survival signaling↓	↔	R, G	Growth and survival suppression	Central hub mechanism reported across multiple tumor models; also supports chemosensitization.
2	Mitochondrial apoptosis	MMP↓; Bax↑; Bcl-2↓; cytochrome c↑; caspase-9/3↑	↔ or lower sensitivity	R, G	Intrinsic apoptosis execution	One of the most consistent anticancer endpoints, usually downstream of stress and survival-pathway suppression.
3	Mitochondrial ROS stress	ROS↑ (context-dependent); oxidative stress↑; lipid peroxidation↑	ROS↓ or antioxidant protection (context-dependent)	P, R, G	Stress amplification	Direction is dose- and model-dependent; cancer models often show pro-oxidant stress, while normal injury models may show antioxidant behavior.
4	ER stress and UPR	ER stress↑; GRP78↑; UPR↑; autophagy or apoptosis↑	↔	R, G	Stress-to-death coupling	Important in several chrysin cancer models and in some drug-combination effects.
5	NF-κB inflammatory transcription	NF-κB↓; COX-2↓; IL-6↓; TNF-α↓	Inflammatory injury signaling↓	R, G	Anti-inflammatory and anti-survival signaling	May contribute to reduced proliferation, invasion, and cytokine-driven tumor support.
6	Invasion EMT and MMPs	EMT↓; MMP-2↓; MMP-9↓; uPA↓; migration↓; invasion↓	↔	G	Anti-invasive phenotype	Mechanistically relevant for metastasis models but generally later and context-dependent.
7	Angiogenesis and HIF-1α VEGF signaling	HIF-1α↓; VEGF↓; angiogenic output↓	↔	G	Anti-angiogenic support	Reported in preclinical models; may overlap with oxidative stress and DNA damage response pathways.
8	Glycolysis and metabolic stress	GLUT1↓; HK2↓; LDH↓; PDK1↓; lactate production↓; ATP↓	↔	G	Metabolic suppression	Relevant but less central than apoptosis and survival signaling; strongest interpretation is model-dependent.
9	NRF2 antioxidant axis	NRF2↓ or antioxidant defense↓ (model-dependent)	NRF2↑; SOD↑; GSH↑; catalase↑ (context-dependent)	R, G	Context-dependent redox selectivity	Potentially useful but also interpret carefully because NRF2 activation can be protective in normal cells and sometimes undesirable in cancer cells.
10	Chemosensitization and radiosensitization	Drug-induced toxicity↑; apoptosis↑; resistance signaling↓	Chemoprotection reported in some injury models	G	Adjunct sensitization	Promising preclinical adjunct signal, but not clinically established.
11	Clinical Translation Constraint	Systemic exposure low after native oral dosing	Dose and formulation constraints	G	Translation limitation	Very poor oral bioavailability is the dominant practical constraint; formulation or local GI targeting is likely required.

Time-Scale Flag (TSF): P / R / G

P: 0–30 min (primary/physical–chemical effects; rapid signaling / phosphorylation shifts)
R: 30 min–3 hr (acute stress-response and redox signaling)
G: >3 hr (gene-regulatory adaptation and phenotype-level outcomes)

CYP2C9, CYP2C9: Click to Expand ⟱

Source:

Type:

CYP2C9, cytochrome P450 enzyme
– CYP2C9 is involved in the metabolism of a range of xenobiotics, including several anticancer drugs, which can affect drug efficacy and toxicity.
– Although CYP2C9 is not traditionally considered an oncogene or tumor suppressor, its expression and genetic variants can influence patient responses to chemotherapy.

Scientific Papers found: Click to Expand⟱

6137-

CHr,

Effects of Chrysin and Its Major Conjugated Metabolites Chrysin-7-Sulfate and Chrysin-7-Glucuronide on Cytochrome P450 Enzymes and on OATP, P-gp, BCRP, and MRP2 Transporters

in-vitro,

NA,

CYP2C9↓, OATPs↓, ABCG2↓, BioEnh↝,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Barriers & Transport ⓘ

OATPs↓, 1,

Drug Metabolism & Resistance ⓘ

ABCG2↓, 1, BioEnh↝, 1, CYP2C9↓, 1,
Total Targets: 4

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: CYP2C9, CYP2C9

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells